Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)
Brief Summary: The study is designed to determine whether vorapaxar, when added to the existing standard of care (SOC) for preventing heart attack and stroke (eg, aspirin, clopidogrel) in participants with a known history of atherosclerosis, will yield additional benefit over the existing standard of care without vorapaxar in preventing heart attack and stroke.

The study is also designed to assess risk of bleeding with vorapaxar added to the standard of care versus the standard of care alone.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vorapaxar; Type: EXPERIMENTAL; Interventions: Drug: Vorapaxar | Intervention Type: DRUG; Name: Vorapaxar; Assigned to Arm(s): Vorapaxar | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: clopidogrel treatment after bare metal stent implantation, Drug: clopidogrel after zotarolimus-eluting stent implantation, Drug: clopidogrel after paclitaxel-eluting stent implantation, Drug: clopidogrel after everolimus-eluting stent implantation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel treatment after bare metal stent implantation, Drug: clopidogrel after zotarolimus-eluting stent implantation, Drug: clopidogrel after paclitaxel-eluting stent implantation, Drug: clopidogrel after everolimus-eluting stent implantation | Intervention Type: DRUG; Name: clopidogrel treatment after bare metal stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel treatment after bare metal stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after zotarolimus-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after paclitaxel-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after everolimus-eluting stent implantation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: clopidogrel after zotarolimus-eluting stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after paclitaxel-eluting stent implantation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: clopidogrel after everolimus-eluting stent implantation; Assigned to Arm(s): 2
C: Arm Label: sarpogrelate 300 mg per day; Type: EXPERIMENTAL; Interventions: Drug: sarpogrelate | Arm Label: No sarpogrelate medication; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: sarpogrelate; Assigned to Arm(s): sarpogrelate 300 mg per day
D: Arm Label: Eptifibatide; Type: EXPERIMENTAL; Interventions: Drug: Eptifibatide (Integrilin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eptifibatide (Integrilin); Assigned to Arm(s): Eptifibatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A